New Europe, U.S. diabetes guidelines drop Avandia
LONDON (Reuters) - New international guidelines from two medical societies on treating people with type 2 diabetes no longer recommend the use of GlaxoSmithKline’s drug Avandia.
A revision to guidelines first issued in 2006 by the European Association for the Study of Diabetes and the American Diabetes Association states that Takeda’s Actos may be considered, but a previous reference to Avandia has been dropped.
Sales of Avandia have plummeted in the past year after the drug was linked to risk of heart attack in a pooled analysis of past clinical studies.
The analysis was contested by Glaxo but the company’s chief executive, Andrew Witty, acknowledged on Wednesday after announcing quarterly results that sales had not recovered and the outlook was negative for the drug, which remains on the market.
Both Avandia and Actos belong to same class of drugs, known as glitazones.
The latest treatment recommendations state that lifestyle changes and metformin should be the initial treatment to help people newly diagnosed with type 2 diabetes.
If patients fail to reach target blood sugar goals with this regimen, doctors should then consider adding insulin or a sulfonylurea drug.
“Alternatively, a less preferred and less validated choice includes the addition of pioglitazone (Actos) or a GLP-1 agonist to lifestyle changes and metformin,” the expert panel added.
(Reporting by Ben Hirschler; Editing by Quentin Bryar)
--------------------------------------------------------------------------------------------Related Posts:
LONDON (Reuters) - Long-term use of GlaxoSmithKline’s Avandia and Takeda’s Actos doubles the risk of bone fractures in women with type 2 diabetes, according to a study released on Wednesday. Scientists already knew the two thiazolidinedione (TZD) drugs for diabetes were associated with fractures, but the magnitude of the risk had not been evaluated. “This study shows
Full Post: Diabetes drugs double women’s fracture risk
--------------------------------------------------------------------------------------------
By Julie Steenhuysen CHICAGO (Reuters) - Older diabetics who took GlaxoSmithKline’s Avandia to control their blood sugar had a higher risk of death and heart failure while on the drug than those who took Takeda Pharmaceutical’s Actos, a drug in the same class, U.S. researchers said on Monday. They said the head-to-head comparison confirms prior analyses finding
Full Post: Safety risks higher with Avandia than Actos: study
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - Following gestational diabetes, a type of diabetes that developments during pregnancy and usually goes away after pregnancy, treatment with metformin or intensive lifestyle interventions can prevent or delay diabetes from becoming permanent in the postpartum period, new research shows. Lead author Dr. Robert E. Ratner at Medstar Research Institute in Hyattsville,
Full Post: Metformin can prevent postpartum diabetes
--------------------------------------------------------------------------------------------
By Will Dunham WASHINGTON (Reuters) - Cancer, the world’s No. 2 killer, is even more lethal for people with diabetes, U.S. researchers said on Tuesday. People with diabetes who get cancer are about 40 percent more likely to die in the years following the diagnosis than cancer patients who are not diabetics, according to research published in
Full Post: Cancer even deadlier for people with diabetes
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - For people who have type 2 diabetes, a low-glycemic index diet is significantly better than a high-fiber diet for keeping blood glucose levels down, researchers report Glycemic index, or GI, refers to how rapidly a food causes blood sugar to rise. High-GI foods, like white bread and potatoes, tend to spur
Full Post: Diabetes control better with low-glycemic diet